
Levi & Korsinsky Opens Investigation Into Zevra Therapeutics Selloff
A 24% plunge in Zevra Therapeutics shares on July 24, 2026, has triggered a formal investigation by law firm Levi & Korsinsky. The sharp decline followed a negative opinion from European regulators regarding arimoclomol, the company’s lead treatment candidate for Niemann-Pick disease type C, prompting scrutiny into potential securities law violations.





















